Day One Biopharmaceuticals, INC Form 4 insider transactions

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, had his stock options repriced to $8.99, contingent on a 12-month retention period.

Day One Biopharmaceuticals repriced stock options for General Counsel Adam Dubow to $8.99 per share, aiming to restore incentive value.

Day One Biopharmaceuticals director William Grossman's stock options were repriced to $8.99 per share, contingent on a retention period.

Day One Biopharmaceuticals' Chief Commercial Officer, Lauren Merendino, had over 510,000 stock options repriced to an exercise price of $8.99 per share.

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax liabilities.

Day One Biopharmaceuticals General Counsel Adam Dubow sold 4,365 shares of common stock to cover tax liabilities from Restricted Stock Unit settlements.

Day One Biopharmaceuticals CEO Jeremy Bender acquired shares through RSU vesting and subsequently sold a portion to cover tax liabilities.

Day One Biopharmaceuticals' Chief Commercial Officer, Lauren Merendino, sold shares to cover tax obligations arising from the vesting of Restricted Stock Units.

Day One Biopharmaceuticals CEO Jeremy Bender reported the transfer of over 600,000 shares of common stock from various grantor retained annuity trusts to a revocable family trust as part of estate planning.

Michael Vasconcelles, Head of Research and Development at Day One Biopharmaceuticals, Inc., was granted 346,000 stock options and 226,000 Restricted Stock Units on June 16, 2025.

Day One Biopharmaceuticals, Inc. Director William Grossman was granted 22,500 stock options and 15,000 restricted stock units (RSUs) on June 2, 2025, as part of his compensation.

Day One Biopharmaceuticals, Inc. Director Habib J. Dable was granted 22,500 stock options and 15,000 restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

Day One Biopharmaceuticals, Inc. Director Saira Ramasastry was granted 22,500 stock options and 15,000 restricted stock units, aligning her interests with shareholders.

Day One Biopharmaceuticals, Inc. Director Garland J. Scott received new equity compensation, including stock options and restricted stock units, as disclosed in a recent SEC Form 4 filing.

Day One Biopharmaceuticals, Inc. Director Garry A Nicholson was granted 22,500 stock options and 15,000 deferred restricted stock units, aligning his incentives with long-term company performance.

Day One Biopharmaceuticals, Inc. Director Natalie C. Holles was granted 22,500 stock options and 15,000 deferred restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

John A. Josey, a Director at Day One Biopharmaceuticals, Inc., was granted 22,500 stock options and 15,000 deferred restricted stock units, aligning his interests with shareholder value.

Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) related to tax liability coverage.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to tax liabilities and vesting of Restricted Stock Units (RSUs).

Charles York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) related to tax liability coverage.

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to RSU settlements and tax liabilities.

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition of stock options and restricted stock units.

Day One Biopharmaceuticals CEO Jeremy Bender reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Adam Dubow, General Counsel of Day One Biopharmaceuticals, acquired stock options for 90,000 shares and 59,000 restricted stock units (RSUs) on January 15, 2025, according to a Form 4 filing.

Day One Biopharmaceuticals' Head of R&D, Samuel C. Blackman, sold 30,000 shares of common stock at a weighted average price of $13.3113 per share.

Day One Biopharmaceuticals CEO Jeremy Bender acquired shares through RSU vesting and sold some to cover tax obligations.

Day One Biopharmaceuticals' Head of R&D, Samuel Blackman, reported the acquisition of shares through RSU vesting and a subsequent sale to cover tax liabilities.